Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06481943 · ClinicalTrials.gov registry record
A Prospective Research Investigation of Ischemia Using MCG
A clinical trial of Acute Coronary Syndrome, sponsored by SB Technology.
- Recruiting
- Registry status
- 150
- Enrollment target
- 2
- Study locations
NCT06481943 is a study of Acute Coronary Syndrome that is actively recruiting participants, run by SB Technology. The registered enrollment target is 150 participants, below the 2,718-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06481943, a study of Acute Coronary Syndrome, is actively recruiting participants, sponsored by SB Technology.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.
Conditions Studied
Interventions
- DEVICE Sponsor MCG device (CardiAQ)
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2026-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06481943
The ClinicalTrials.gov registry entry for NCT06481943 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,718-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (94% lower). The listed sponsor is SB Technology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Sponsor MCG device (CardiAQ) is the first listed.
NCT06481943 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT06481943 about?
NCT06481943 is a clinical study titled "A Prospective Research Investigation of Ischemia Using MCG". PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.
What is the current status of trial NCT06481943?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-07-11. Estimated completion is 2026-04.
What conditions does trial NCT06481943 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome.
What interventions are being tested in trial NCT06481943?
The interventions under investigation include: Sponsor MCG device (CardiAQ) (DEVICE).
Who is sponsoring clinical trial NCT06481943?
This trial is sponsored by SB Technology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06481943 being conducted?
This trial has 2 study locations across Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Polypill for Acute Coronary Syndrome
RECRUITING · Phase 2
-
Positive Emotions Following Acute Cardiac Events
RECRUITING · NA
-
Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock
RECRUITING
-
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
RECRUITING · Phase 3
-
AngelMed Guardian® System PMA Post Approval Study
RECRUITING
-
Online Tai Chi Plus Fitbit After ACS
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.